REGULATory T-Cell Inhibition With Basiliximab (Simulect) During Recovery From Therapeutic Temozolomide-induced Lymphopenia During Antitumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 May 2018
At a glance
- Drugs Basiliximab (Primary) ; Cancer vaccine-pp65 (Primary) ; Autolymphocyte therapy; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Acronyms REGULATe
- 31 Aug 2018 Biomarkers information updated
- 05 Apr 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
- 05 Apr 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.